Lindsey Hartley serves as the Chief Financial Officer (CFO) at AxoGen Inc., a pioneering biotechnology company focused on advancing peripheral nerve repair and regeneration. With more than 20 years of experience in financial leadership within the healthcare and life sciences industries, Lindsey began her career at Deloitte & Touche, where she specialized in audit and advisory services for biotech firms. She later advanced to senior finance roles at Stryker Corporation and Integra LifeSciences, gaining expertise in strategic financial planning, capital raising, and regulatory compliance in fast-paced, innovation-driven environments. Lindsey's notable achievements include orchestrating a $300 million equity financing round at her prior role, which fueled product development and market expansion, and spearheading cost-optimization programs that boosted operating margins by 22%. Recognized as a Forbes Finance Council member and recipient of the CFO Leadership Award from the Healthcare Financial Management Association, she has a proven track record of transforming financial strategies into sustainable growth, particularly in navigating SEC filings, M&A transactions, and investor communications. At AxoGen, Lindsey directs all financial operations, including budgeting, forecasting, treasury management, and risk assessment, while collaborating closely with the executive team to support R&D investments and commercial scaling. Her visionary approach ensures fiscal discipline amid the company's ambitious pipeline of nerve repair technologies, positioning AxoGen for long-term profitability and shareholder value in the regenerative medicine sector.